EFFECT OF CARDIAC TISSUE SPECIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITION

心肌组织特异性血管紧张素转换酶抑制的作用

• 批准号: 6114166
• 负责人: LAWRENCE S. ZISMAN
• 金额: $ 3.22万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114166
• 关键词: ACE inhibitors; angiotensin II; clinical research; drug screening /evaluation; enalapril; heart disorder chemotherapy; heart metabolism; human subject; human therapy evaluation; idiopathic dilated cardiomyopathy; muscle stress; norepinephrine; peptidyl dipeptidase A; pharmacogenetics

Our hypotheses is that 1) in patients with idiopathic dilated cardio- myopathy, administration of the cardiac tissue specific ace-inhibitor, quinapril, significantly suppresses angiotensin II formation compared to enalapril The suppression is more pronounced in patients with the ace D/D genotype and 2) the additional suppression of ANG II afforded by quinapril correlates with a reduction in left ventricular (LV) wall stress, transmyocardial norepinephrine, and the net balance of cardiac protein synthesis.

我们的假设是：1) 在特发性扩张型心肌病患者中，与依那普利相比，给予心脏组织特异性 ACE 抑制剂喹那普利可显着抑制血管紧张素 II 的形成。这种抑制在 ACE D/D 基因型患者中更为明显；2) 喹那普利对 ANG II 的额外抑制与左心室收缩压降低相关 (LV) 壁应力、跨心肌去甲肾上腺素和心脏蛋白质合成的净平衡。